shire map
Select a
Location

Shire  Global

List of Shire Products

ADVATE® (octocog alfa) – Marketing Authorisation Holder Baxalta
 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

CINRYZE® black triangle(C1 inhibitor [human]) – Marketing Authorisation Holder Shire 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

CUVITRU® black triangle(human normal immunoglobulin) – Marketing Authorisation Holder Baxalta

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

ELAPRASE® black triangle (Idursulfase) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

ELVANSE® black triangle (lisdexamfetamine dimesylate) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

EQUASYM® (methylphenidate hydrochloride) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

FEIBA® (factor VIII inhibitor bypassing fraction) – Marketing Authorisation Holder Baxalta

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

FIRAZYR® (icatibant acetate) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

HYQVIA® black triangle (human normal immunoglobulin) – Marketing Authorisation Holder Baxalta

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

INTUNIV® black triangle (guanfacine hydrochloride) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

KIOVIG® (human immunoglobulin) – Marketing Authorisation Holder Baxalta

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

OBIZUR® black triangle (porcine factor viii:c, antihaemophilic factor, susoctocog alfa) – Marketing Authorisation Holder Baxalta

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

PLENADREN® (hydrocortisone) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

REPLAGAL® (agalsidase alfa) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

REVESTIVE® black triangle (teduglutide) – Marketing Authorisation Holder Shire
 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

RIXUBIS® black triangle (nonacog gamma) – Marketing Authorisation Holder Baxalta

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. UK: Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

VPRIV® (velaglucerase alfa) – Marketing Authorisation Holder Shire

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Shire Pharmaceuticals Ltd by email at drugsafety@shire.com.

TOP

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our privacy notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE